Back to Research Home
ARGXargenx NV ADR
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
$873.71−0.23%
As of 23 Oct 2026Mkt cap —
Stage 13
WAIT
Fundamentals
—/75
Technical
11.5/15
Independent
—/90
GCAE viewevidence is stale or freshness is unknown
Price
- 1M
- −9.2%
- 3M
- −1.7%
- 6M
- +12.0%
- 1Y
- +7.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -1196.2%
- FCF margin
- -1185.2%
- Current ratio
- 5.2x
Growth
- Revenue growth
- +254.4%Latest FY YoY
- Revenue CAGR
- −73.3%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +7.5%3Y annualised
- Net cash
- $3.4B-5.0x OCF
Annual trend
- CAGR 2021–2023
- −73.3%
- Latest · 2023
- $0B
- YoY
- +254.4%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
evidence is stale or freshness is unknown
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded